Corvus Pharmaceuticals, Inc. (CRVS): Price and Financial Metrics
CRVS Price/Volume Stats
| Current price | $3.24 | 52-week high | $3.70 |
| Prev. close | $3.20 | 52-week low | $0.61 |
| Day low | $3.10 | Volume | 387,791 |
| Day high | $3.49 | Avg. volume | 524,538 |
| 50-day MA | $1.68 | Dividend yield | N/A |
| 200-day MA | $1.06 | Market Cap | 150.88M |
CRVS Stock Price Chart Interactive Chart >
Corvus Pharmaceuticals, Inc. (CRVS) Company Bio
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. The company was founded in 2014 and is based in Burlingame, California.
Latest CRVS News From Around the Web
Below are the latest news stories about CORVUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRVS as an investment opportunity.
Biotech Alert: Searches Spiking For These Stocks Today - Friday, June 2Various names in the biotech sector are seeing a substantial increase in search activity today. Such names include the likes of Akebia Therapeautics, Corvus Pharmaceuticals, and Mirati Therapeutics. |
3 High-Potential Penny Stocks to Buy NowWhen it comes to penny stocks to buy now, be aware of the risks. |
Corvus Pharmaceuticals to Present at the Jefferies Healthcare ConferenceBURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer of Corvus, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Healthcare Conference, which is being held in New York from June 7-9. The presentation will be on Wednesday, June 7, 2023 at 9:30 am ET. A webcast of the presentatio |
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year. |
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant LymphomaBURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company’s ITK inhibitor, at the International Conference on Malignant Lymphoma (ICML) meeting, which is taking place June 13-17, 2023 in Lugano, Switzerland. “We continue to make strong progress in the development of ITK inhibition as a potential platform opportunity with a novel mechanism of a |
CRVS Price Returns
| 1-mo | 170.00% |
| 3-mo | 359.57% |
| 6-mo | 217.65% |
| 1-year | 205.66% |
| 3-year | -1.22% |
| 5-year | -75.04% |
| YTD | 281.18% |
| 2022 | -64.73% |
| 2021 | -32.30% |
| 2020 | -34.56% |
| 2019 | 48.23% |
| 2018 | -64.58% |
Loading social stream, please wait...